Twice-daily cough syrup Tuzistra XR launched in the US
8 September 2015 | By Victoria White
Tuzistra XR is the only codeine-based extended-release cough cold syrup available to patients and physicians in the United States...
List view / Grid view
News
NSCLC treatment market value to approach $11 billion by 2021
8 September 2015 | By Victoria White
This increase will be driven primarily by the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, says GBI Research...
First patient dosed in Phase I trial of universal HIV vaccine Pennvax-GP
8 September 2015 | By Victoria White
The trial will measure immune responses following administration of Pennvax-GP in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12)...
Phenomenex and Tecan to co-market automated sample preparation solutions
8 September 2015 | By Tecan
Phenomenex, Inc. and the Tecan Group (SIX Swiss Exchange: TECN) today announced a collaboration to co-market automated solid phase extraction (SPE) sample preparation solutions...
Sanifit raises €36.6 million to advance SNF472
8 September 2015 | By Victoria White
SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in patients with end stage renal disease...
Opdivo demonstrates sustained survival results in squamous NSCLC
8 September 2015 | By Victoria White
In two studies, Opdivo showed an estimated 18 month overall survival rate of 27% to 28% in patients with previously treated squamous non-small cell lung cancer (NSCLC)...
Responsible Person training supported by MHRA Inspectorate
7 September 2015 | By Victoria White
The MHRA has said it is now seeing greater appreciation among pharmaceutical sector companies of the skills required for the essential Responsible Person role...
Cherwell appoints Harshad Joshi as new Quality Manager
7 September 2015 | By Cherwell Laboratories
Company maintains focus on quality to meet customer expectations...
23 drugs to be axed from the Cancer Drug Fund
7 September 2015 | By Victoria White
The announcement follows a review that found that CDF spending would rise to around £410 million for this year - an over-spend of £70m from the budget set in April 2015...
NICE recommends melanoma drug pembrolizumab
7 September 2015 | By Victoria White
NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...
Celyad appoints Dr Debasish Roychowdhury as non-executive director
7 September 2015 | By Victoria White
Dr Roychowdury brings over 15 years of comprehensive pharmaceutical industry experience and 14 years of patient care and academic research to the role with Celyad...
Faron announces intention to float on AIM
7 September 2015 | By Victoria White
Faron's admission to AIM will support development of its lead candidate, Traumakine, into a Phase III Study and the development of its preclinical cancer immunotherapy candidate, Clevegen...
EC approves multiple myeloma treatment Farydak
4 September 2015 | By Victoria White
The EC has approved Farydak in combination with bortezomib and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma...
NICE recommends RoActemra for severe rheumatoid arthritis
4 September 2015 | By Victoria White
RoActemra has been recommended by NICE for the treatment of patients with severe rheumatoid arthritis whose disease has not responded to intensive therapy with a combination of cDMARDs...
FDA approves label expansion for AstraZeneca’s Brilinta
4 September 2015 | By Victoria White
The FDA has approved Brilinta tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year...
